Tanshinone IIA promotes non‑amyloidogenic processing of amyloid precursor protein in platelets via estrogen receptor 
signaling to phosphatidylinositol 3-kinase/Akt

Shi,Chun; Zhu,Xiaoming; Wang,Jisheng; Long,Dahong

doi:10.3892/br.2014.263

Tanshinone IIA promotes non‑amyloidogenic processing of amyloid precursor protein in platelets via estrogen receptor signaling to phosphatidylinositol 3-kinase/Akt

Authors:
- Chun Shi
- Xiaoming Zhu
- Jisheng Wang
- Dahong Long
View Affiliations

Affiliations: Department of Anatomy, Guangzhou Medical University, Guangzhou, Guangdong, P.R. China, Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
Published online on: March 24, 2014 https://doi.org/10.3892/br.2014.263
Pages: 500-504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amyloid β peptide (Aβ) is a proteolytic product of amyloid precursor protein (APP). Recent findings suggested that platelet-derived Aβ is closely associated with the pathogenesis of atherosclerosis (AS). Tanshinone IIA (Tan IIA), a pharmacologically active component of the Chinese herb Salvia miltiorrhiza Bunge, has long been used to treat AS and was also identified as a phytoestrogen. However, it has not been elucidated whether Tan IIA intervenes with platelet APP processing and whether such an intervention is associated with its estrogenic activity. Using human platelets, this study demonstrated that Tan IIA promoted the non‑amyloidogenic cleavage of APP via estrogenic activity. The phosphatidylinositol 3-kinase̸Akt pathway may be involved in this effect of Tan IIA on platelet APP metabolism as a downstream effector of estrogen receptor signaling. This study aimed to extend the existing data and provide new insights into the mechanism underlying the vasoprotective effect of Tan IIA.

View Figures

View References

1	Shi C, Na N, Zhu X and Xu J: Estrogenic effect of ginsenoside Rg1 on APP processing in post-menopausal platelets. Platelets. 24:51–62. 2013. View Article : Google Scholar : PubMed/NCBI
2	Gandy S and DeKosky ST: Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu Rev Med. 64:367–383. 2013.
3	Mandel S, Amit T, Reznichenko L, Weinreb O and Youdim MB: Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res. 50:229–234. 2006. View Article : Google Scholar : PubMed/NCBI
4	Li QX, Fuller SJ, Beyreuther K and Masters CL: The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol. 66:567–574. 1999.PubMed/NCBI
5	Kokjohn TA, Van Vickle GD, Maarouf CL, et al: Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta. 1812.1508–1514. 2011.PubMed/NCBI
6	Howlett GJ and Moore KJ: Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol. 17:541–547. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fan GW, Gao XM, Wang H, et al: The anti-inflammatory activities of tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI
8	Xu S, Little PJ, Lan T, et al: Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys. 515:72–79. 2011. View Article : Google Scholar : PubMed/NCBI
9	Gao S, Liu Z, Li H, Little PJ, Liu P and Xu S: Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 220:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
10	Fan G, Zhu Y, Guo H, Wang X, Wang H and Gao X: Direct vasorelaxation by a novel phytoestrogen tanshinone IIA is mediated by nongenomic action of estrogen receptor through endothelial nitric oxide synthase activation and calcium mobilization. J Cardiovasc Pharmacol. 57:340–347. 2011. View Article : Google Scholar
11	Shi C, Zheng DD, Fang L, Wu F, Kwong WH and Xu J: Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim Biophys Acta. 1820.453–460. 2012.PubMed/NCBI
12	Shi C, Wu F, Xu J and Zou J: Bilobalide regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. Neurochem Int. 59:59–64. 2011. View Article : Google Scholar : PubMed/NCBI
13	Shi C, Zheng DD, Wu FM, Liu J and Xu J: The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3β pathway mediates bilobalide-induced reduction in amyloid β-peptide. Neurochem Res. 37:298–306. 2012.PubMed/NCBI
14	Grove-Strawser D, Boulware MI and Mermelstein PG: Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neurosci. 170:1045–1055. 2010. View Article : Google Scholar
15	Gilad LA and Schwartz B: Association of estrogen receptor beta with plasma-membrane caveola components: implication in control of vitamin D receptor. J Mol Endocrinol. 38:603–618. 2007. View Article : Google Scholar : PubMed/NCBI
16	Chambliss KL, Yuhanna IS, Mineo C, et al: Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res. 87:E44–E52. 2000. View Article : Google Scholar : PubMed/NCBI
17	Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K and Wehling M: Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 83:965–1016. 2003.PubMed/NCBI
18	Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 407:538–541. 2000. View Article : Google Scholar : PubMed/NCBI